Neonatal neuroblastoma

Seminars in Fetal and Neonatal Medicine

Volumn 17, Issue 4, 2012, Pages 207-215

  Fisher, Jonathan P H ^a   Tweddle, Deborah A ^a,b  

^a Infectious Diseases Allergy   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Genetics; MYCN; Neonate; Neuroblastoma; Screening; Spinal cord compression

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CATECHOLAMINE; HOMEODOMAIN PROTEIN; PAIRED HOMEOBOX 2B; UNCLASSIFIED DRUG;

ADRENAL TUMOR; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER RISK; CANCER SCREENING; CATECHOLAMINE SYNTHESIS; CATECHOLAMINE URINE LEVEL; CHILDHOOD CANCER; CHROMOSOME ABERRATION; CLINICAL FEATURE; FAMILIAL CANCER; FAMILY HISTORY; GENE MUTATION; GENETIC SCREENING; HISTOLOGY; HORNER SYNDROME; HUMAN; HYPOVENTILATION; METASTASIS; MIOSIS; NEONATAL NEUROBLASTOMA; NEUROBLASTOMA; NEWBORN DISEASE; NEWBORN SCREENING; NUCLEAR MAGNETIC RESONANCE IMAGING; PLOIDY; PRENATAL DIAGNOSIS; PRIMARY TUMOR; PTOSIS; REVIEW; SPINAL CORD COMPRESSION; STEROID THERAPY; THORAX RADIOGRAPHY; TUMOR GROWTH; TUMOR LOCALIZATION; TUMOR REGRESSION;

DIAGNOSIS, DIFFERENTIAL; FAMILY HEALTH; HOMEODOMAIN PROTEINS; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; MUTATION; NEUROBLASTOMA; OPSOCLONUS-MYOCLONUS SYNDROME; PROGNOSIS; RECEPTOR PROTEIN-TYROSINE KINASES; SPINAL CORD COMPRESSION; TRANSCRIPTION FACTORS;

EID: 84862264397     PISSN: 1744165X     EISSN: 18780946     Source Type: Journal    
DOI: 10.1016/j.siny.2012.05.002     Document Type: Review

References (46)

1. Stiller C.A., Allen M.B., Eatock E.M. Childhood cancer in Britain: The National Registry of Childhood Tumours and Incidence Rates 1978-1987. Eur J Cancer 1995, 31A:2028-2034.
2. Cotterill S.J., Parker L., Malcolm A.J., et al. Incidence and survival for cancer in children and young adults in the North of England, 1968-1995: a report from the Northern Region Young Persons' Malignant Disease Registry. Br J Cancer 2000, 83:397-403.
3. Goodman M.T., Gurney J.G., Smith M.A., Olshan A.F. Sympathetic nervous system tumours. Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995 1999, Bethesda, MD. L.A.G. Ries, M.A. Smith, J.G. Gurney (Eds.).
4. Dhir S., Wheeler K. Neonatal neuroblastoma. Early Hum Dev 2010, 86:601-605.
5. Cotterill S.J., Pearson A.D.J., Pritchard J., et al. Clinical prognostic factors in 1277 patients with neuroblastoma: results of the European Neuroblastoma Study Group survey 1982-1992. Eur J Cancer 2000, 36:901-908.
6. Olshan A.F., Bunin G.R. Epidemiology of neuroblastoma. Neuroblastoma 2000, Elsevier, Amsterdam. G.M. Brodeur, T. Sawada, Y. Tsuchida, P.A. Voute (Eds.).
7. Neelanjana M., Sabaratnam A. Malignant conditions in children born after assisted reproductive technology. Obstet Gynecol Surv 2008, 63:669-676.
8. Maris J.M. Recent advances in neuroblastoma. N Engl J Med 2010, 362:2202-2211.
9. Deyell R.J., Attiyeh E.F. Advances in the understanding of constitutional and somatic genomic alterations in neuroblastoma. Cancer Genet 2011, 204:113-121.
10. Maris J.M., Matthay K.K. Molecular biology of neuroblastoma. J Clin Oncol 1999, 17:2264-2279.
11. Maris J.M., Kyemba S.M., Rebbeck T.R., et al. Molecular genetic analysis of familial neuroblastoma. Eur J Cancer 1997, 33:1923-1928.
12. Janoueix-Lerosey I., Lequin D., Brugieres L., et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 2008, 455(7215):967-970.
13. Mosse Y.P., Laudenslager M., Longo L., et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008, 455(7215):930-935.
14. Chiarle R., Voena C., Ambrogio C., Piva R., Inghirami G. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 2008, 8:11-23.
15. Trochet D., Bourdeaut F., Janoueix-Lerosey I., et al. Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma. Am J Hum Genet 2004, 74:761-764.
16. Mosse Y.P., Laudenslager M., Khazi D., et al. Germline PHOX2B mutation in hereditary neuroblastoma. Am J Hum Genet 2004, 75:727-730.
17. Trochet D., O'Brien L.M., Gozal D., et al. PHOX2B genotype allows for prediction of tumor risk in congenital central hypoventilation syndrome. Am J Hum Genet 2005, 76:421-426.
18. van Limpt V., Schramm A., van Lakeman A., et al. The Phox2B homeobox gene is mutated in sporadic neuroblastomas. Oncogene 2004, 23:9280-9288.
19. Bentires-Alj M., Paez J.G., David F.S., et al. Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res 2004, 64:8816-8820.
20. Nuchtern J.G. Perinatal neuroblastoma. Semin Pediatr Surg 2006, 15:10-16.
21. Brodeur G.M., Maris J.M. Neuroblastoma. Principles and practice of pediatric oncology 2001, 895-937. Lippincott-Raven, Philadelphia, Ch. 29. P.A. Pizzo, D.G. Poplack (Eds.).
22. Moppett J., Haddadin I., Foot A.B. Neonatal neuroblastoma. Archs Dis Childh 1999, 81:F134-F137.
23. George N.D., Gonzalez G., Hoyt C.S. Does Horner's syndrome in infancy require investigation?. Br J Ophthalmol 1998, 82:51-54.
24. Brodeur G.M., Pritchard J., Berthold F., et al. Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. J Clin Oncol 1993, 11:1466-1477.
25. Shimada H., Ambros I.M., Dehner L., et al. The international neuroblastoma pathology classification (the Shimada system). Cancer 1999, 86:364-372.
26. Shimada H., Ambros I., Dehner L., et al. Terminology and morphologic criteria of neuroblastic tumors. Recommendations by the International Neuroblastoma Pathology Committee. Cancer 1999, 86:349-363.
27. Schwab M., Alitalo K., Klempnauer K.-H., et al. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature 1983, 305:245-248.
28. Cohn S.L., Tweddle D.A. MYCN amplification remains prognostically strong 20 years after its " clinical debut" . Eur J Cancer 2004, 40:2639-2642.
29. Attiyeh E.F., London W.B., Mosse Y.P., et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med 2005, 353:2243-2253.
30. Bown N., Cotterill S., Lastowska M., et al. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med 1999, 340:1954-1961.
31. Brodeur G.M. Neuroblastoma: biological insights into a clinical enigma. Nature Rev 2003, 3:203-216.
32. Janoueix-Lerosey I., Schleiermacher G., Michels E., et al. Overall genomic pattern is a predictor of outcome in neuroblastoma. J Clin Oncol 2009, 27:1026-1033.
33. Ambros I.M., Brunner B., Aigner G., et al. A multilocus technique for risk evaluation of patients with neuroblastoma. Clin Cancer Res 2011, 17:792-804.
34. Schleiermacher G., Michon J., Ribeiro A., et al. Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study). Br J Cancer 2011, 105:1940-1948.
35. Cohn S.L., Pearson A.D., London W.B., et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol 2009, 27:289-297.
36. Rubie H., De Bernardi B., Gerrard M., et al. Excellent outcome with reduced treatment in infants with nonmetastatic and unresectable neuroblastoma without MYCN amplification: results of the prospective INES 99.1. J Clin Oncol 2010, 29:449-455.
37. De Bernardi B., Mosseri V., Rubie H., et al. Treatment of localised resectable neuroblastoma. Results of the LNESG1 study by the SIOP Europe Neuroblastoma Group. Br J Cancer 2008, 99:1027-1033.
38. De Bernardi B., Gerrard M., Boni L., et al. Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without MYCN gene amplification. J Clin Oncol 2009, 27:1034-1040.
39. Canete A., Gerrard M., Rubie H., et al. Poor survival for infants with MYCN-amplified metastatic neuroblastoma despite intensified treatment: the International Society of Paediatric Oncology European Neuroblastoma Experience. J Clin Oncol 2009, 27:1014-1019.
40. De Bernardi B., Balwierz W., Bejent J., et al. Epidural compression in neuroblastoma: diagnostic and therapeutic aspects. Cancer Lett 2005, 228:283-299.
41. Maris J.M., Woods W.G. Screening for neuroblastoma: a resurrected idea?. Lancet 2008, 371(9619):1142-1143.
42. Hiyama E., Iehara T., Sugimoto T., et al. Effectiveness of screening for neuroblastoma at 6 months of age: a retrospective population-based cohort study. Lancet 2008, 371(9619):1173-1180.
43. Friedman D.L., Kadan-Lottick N.S., Whitton J., et al. Increased risk of cancer among siblings of long-term childhood cancer survivors: a report from the childhood cancer survivor study. Cancer Epidemiol Biomarkers Prev 2005, 14:1922-1927.
44. Johnson R.H., Park J.R. ALK-related neuroblastoma susceptibility. GeneReviews 2010, University of Washington, Seattle. R.A. Pagon, T.D. Bird, C.R. Dolan, K. Stephens, M.P. Adam (Eds.).
45. Pussard E., Neveux M., Guigueno N. Reference intervals for urinary catecholamines and metabolites from birth to adulthood. Clin Biochem 2009, 42:536-539.
46. Combaret V., Bergeron C., Noguera R., Iacono I., Puisieux A. Circulating MYCN DNA predicts MYCN-amplification in neuroblastoma. J Clin Oncol 2005, 23:8919-8920. author reply 8920.